KRAS and neoplasm: One example of prognostic score refinement is the addition of KRAS mutational status to the Clinical Risk Score, originally defined with standard clinical and pathological variables.17 Subsequent refinements, including additional relevant mutations, improved prognostic modeling but remain imperfect in part due to tumor heterogeneity in patients with multiple metastases.18